Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 95

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 95
---
 other third
parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby endangering
our ability to seek patent protection. In addition, publications of discoveries in the scientific and scholarly literature often lag
behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published
until 18 months after filing, or in some cases not at all. Consequently, we cannot be certain that we were the first to file for
patent protection on the inventions claimed in our patents or pending patent applications.

<div align='center'>48</div>

The issuance or grant of
a patent is not irrefutable as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts
or patent offices in the United States and abroad. There may be prior art of which we are not aware that may affect the validity
or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity
or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. We may
in the future, become subject to a third-party pre-issuance submission of prior art or opposition, derivation, revocation, re-examination,
post-grant or inter partesreview, or interference proceedings or other similar proceedings challenging our patent rights or the
patent rights of others in the USPTO or other foreign patent office. An unfavorable determination in any such submission, proceeding
or litigation could reduce the scope of or invalidate our patent rights, allow third parties to commercialize our technology or products
and compete directly with us, without payment to us, or extinguish our ability to manufacture or commercialize products without infringing
third-party patent rights.

Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts, and could increase our costs.

Our commercial success depends
in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation
involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative
proceedings for challenging patents, including interference, reexamination, and post grant review proceedings before the USPTO or oppositions
and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties
having patent or